about
Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG)Reversible mitochondrial DNA accumulation in nuclei of pluripotent stem cellsThe p53-PUMA axis suppresses iPSC generationIn Vitro Differentiation Potential of Human Placenta Derived Cells into Skin Cells.Applications of amniotic membrane and fluid in stem cell biology and regenerative medicine.The hematopoietic system in the context of regenerative medicine.New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cellsCyclin-dependent kinase inhibitor p21 controls adult neural stem cell expansion by regulating Sox2 gene expressionEmbryonic stem cells or induced pluripotent stem cells? A DNA integrity perspective.Regulation of DNA Replication in Early Embryonic Cleavages.From "ES-like" cells to induced pluripotent stem cells: a historical perspective in domestic animals.Concise review: induced pluripotency by defined factors: prey of oxidative stress.Potential applications of keratinocytes derived from human embryonic stem cells.Stem cells and their potential clinical applications in psychiatric disorders.Clinical potential of human-induced pluripotent stem cells : Perspectives of induced pluripotent stem cells.Bmi1-mediated epigenetic signature acts as a critical barrier for direct reprogramming to mature cardiomyocytesGeneration of iPSCs from genetically corrected Brca2 hypomorphic cells: implications in cell reprogramming and stem cell therapy.Histone chaperone APLF regulates induction of pluripotency in murine fibroblasts.Ethical and Safety Issues of Stem Cell-Based Therapy.
P2860
Q27311626-4A34A85A-0D1F-4CA0-8646-36DE76C1DD7BQ28652863-CBBE625D-5270-459E-9CE9-C0105D3DD90DQ35375977-707756C4-FD91-426D-B8E1-85857A420D94Q35852403-CE5F37D5-58ED-4ACC-89A7-04BED901DEE0Q36326880-FCFBE225-F829-4944-B735-04A952659E20Q36627127-394C6D16-71A0-403C-9081-CBBBD66E52F6Q36945734-066D7426-20DA-48E4-9313-FA86B6C3E056Q37023123-156AEDAA-2D9E-4C42-8E76-9FA5A4030437Q37627420-7643C436-C524-42CE-88C4-BA5CE183A799Q37628282-022A3C28-599F-452A-95C4-E2E52517965EQ38166000-552B089E-9B0B-4C26-88AE-679B028C64EFQ38320762-12A6E7E8-BF5C-4FE2-B956-AA5E996323B5Q38668504-86A6EBCE-394C-4436-9094-92675B9D3EBEQ38691835-B551E856-D9BB-4B19-9558-68BBB927C907Q39024182-E7248FBB-1CB3-4D27-9F63-FAB61FF13C30Q42362830-CEA95D1E-8540-4004-85F5-942A705A1A8FQ45861515-075DCF53-8D3E-4E2C-9236-D5FD57CF1C63Q46460714-54EE43D2-681C-48C8-8B2F-CA77B846489FQ50050571-B3128F92-B5FE-4885-90E7-F674D3D844FD
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genomic instability in iPS: time for a break
@ast
Genomic instability in iPS: time for a break
@en
Genomic instability in iPS: time for a break
@nl
type
label
Genomic instability in iPS: time for a break
@ast
Genomic instability in iPS: time for a break
@en
Genomic instability in iPS: time for a break
@nl
prefLabel
Genomic instability in iPS: time for a break
@ast
Genomic instability in iPS: time for a break
@en
Genomic instability in iPS: time for a break
@nl
P2860
P50
P356
P1433
P1476
Genomic instability in iPS: time for a break
@en
P2860
P304
P356
10.1038/EMBOJ.2011.50
P407
P577
2011-03-01T00:00:00Z